Loading...

SPRO SPERO THERAPEUTICS INC Management Changes 8-K Filing

SPR

SPR

SPERO THERAPEUTICS INC

(SPRO)

2026 8-K

Q1 Results Announcement

Q4 Results Announcement

Management Change

Milestone Payment Announcement

Quarterly Results

Product Expansion

Financial Statements

Earnings Report

SEC Investigation

Q3 Earnings Report

Workforce Reduction

Investor Update

Earnings Reports

Amendment to Stock Incentiv...

Annual Meeting Announcement

Financial Results Announcement

Departure of Directors or C...

Presentation Update

Financial Condition

Clinical Trial Announcement

Earnings Reports

Appointment of Esther Rajav...

Amendment to Filing

Stock Incentive Plan Amendment

Earnings Reports

FDA Agreement for Phase 3 C...

Earnings Report

Financial Results Announcement

Appointment of Chief Operat...

Financial Condition

External Links:

On January 30, 2026, Dr. Ankit Mahadevia resigned from the Board of Spero Therapeutics due to other commitments, effective immediately; additionally, on January 20, 2026, the SEC concluded its investigation and will not recommend enforcement action against the company.

AI Assistant

SPERO THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.